阿立哌唑和利培酮治疗首发精神分裂症的疗效观察

Controlled Study of Aripiprazole and Risperidone in the Treatment of Initial Schizophrenia

目的:探讨以利培酮为对照与阿立哌唑治疗首发精神分裂症的疗效和不良反应。方法:78例符合CCMD-3诊断标准的首发精神分裂症患者随机分为两组,分别给予阿立哌唑和利培酮治疗8周。采用阳性症状和阴性症状量表(PANSS)评定临床疗效,副作用量表((TESS)评定药物不良反应。结果:治疗8周的疗效相当,阿立哌唑组和利培酮组的有效率差异无统计学意义(P>0.05),阿立哌唑组的不良反应(锥体外系、体重增加、月经紊乱)的发生率明显低于利培酮组(P<0.05)。结论:阿立哌唑和利培酮对首发精神分裂症的疗效相当,不良反应较小。

Objective： To investigate the efficacy and side effects of tripiprazole in the treatment of the initial schizophrenia and its comparison with risperidone. Method： 78 cases meeting the CCMD-3 criteria for the initial schizo- phrenia were randomly divided into two groups treated with aripiprazole and risperidone respectively for 8 weeks. The posi- tive and negative Syndrome scale（PANSS） and treatment emergent symptom scale （TESS） were used to assess the therapeutic efficacy and side effects, respectively. Result： Aripiprazole was as effective as risperidone for the treatment of the initial schizophrenia （ P 〉 0.05 ） , and there was no obvius difference between the two groups in the significant improvemrnt rate （P 〉 0. 05 ）. But aripiprazole produced fewer side effects than risperidone, such as extrapyramidal symptom, gain weight, disorder of menstruation. Conclusion： Aripiprazole is as effective as risperidone for the treatment of the initial schizophrenia and has fewer side effects.